Anna L. Eichenberger

Bern, BE, Switzerland

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 19 publications

Primary bedaquiline-resistant tuberculosis in an Afghan migrant to Switzerland: Diagnostic and treatment challenges in a high-resource setting.

Primary bedaquiline-resistant tuberculosis in an Afghan migrant to Switzerland: Diagnostic and treatment challenges in a high-resource setting.

Journal: International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases

Published: March 28, 2026

PrEP Cascade and Barriers Among Serodifferent Couples in Rural Tanzania: A Prospective Study on Awareness, Uptake, Adherence, and Retention.

PrEP Cascade and Barriers Among Serodifferent Couples in Rural Tanzania: A Prospective Study on Awareness, Uptake, Adherence, and Retention.

Journal: AIDS and behavior

Published: October 25, 2025

Mental health management in the context of TB care in the WHO European Region: a consensus statement.

Mental health management in the context of TB care in the WHO European Region: a consensus statement.

Journal: IJTLD open

Published: October 10, 2025

Viable Schistosoma mansoni infection 41 years after last exposure-a case report of a loyal parasite.

Viable Schistosoma mansoni infection 41 years after last exposure-a case report of a loyal parasite.

Journal: Journal of travel medicine

Published: June 19, 2025

Infection with Mycobacterium tuberculosis alters the antibody response to HIV-1.

Infection with Mycobacterium tuberculosis alters the antibody response to HIV-1.

Journal: PLoS pathogens

Published: February 12, 2025

Body weight changes in people with HIV starting dolutegravir versus efavirenz-based regimens in a large cohort in rural Tanzania.

Body weight changes in people with HIV starting dolutegravir versus efavirenz-based regimens in a large cohort in rural Tanzania.

Journal: AIDS (London, England)

Published: July 11, 2024

Antibody and T-Cell Response to Bivalent Booster SARS-CoV-2 Vaccines in People With Compromised Immune Function: COVERALL-3 Study.

Antibody and T-Cell Response to Bivalent Booster SARS-CoV-2 Vaccines in People With Compromised Immune Function: COVERALL-3 Study.

Journal: The Journal of infectious diseases

Published: February 01, 2024

Bridging the gap: identifying factors impacting mRNA severe acute respiratory syndrome coronavirus 2 vaccine booster response in people with HIV-1.

Bridging the gap: identifying factors impacting mRNA severe acute respiratory syndrome coronavirus 2 vaccine booster response in people with HIV-1.

Journal: AIDS (London, England)

Published: October 13, 2023

Antibody Response After the Third SARS-CoV-2 Vaccine in Solid Organ Transplant Recipients and People Living With HIV (COVERALL-2).

Antibody Response After the Third SARS-CoV-2 Vaccine in Solid Organ Transplant Recipients and People Living With HIV (COVERALL-2).

Journal: Open forum infectious diseases

Published: July 06, 2023

Transitioning to Dolutegravir in a Programmatic Setting: Virological Outcomes and Associated Factors Among Treatment-Naive Patients With HIV-1 in the Kilombero and Ulanga Antiretroviral Cohort in Rural Tanzania.

Transitioning to Dolutegravir in a Programmatic Setting: Virological Outcomes and Associated Factors Among Treatment-Naive Patients With HIV-1 in the Kilombero and Ulanga Antiretroviral Cohort in Rural Tanzania.

Journal: Open forum infectious diseases

Published: March 21, 2023

Improving anaemia diagnosis using peripheral blood smear with remote interpretation in adults living with HIV with moderate to severe anaemia: A prospective study nested within the Kilombero and Ulanga antiretroviral cohort.

Improving anaemia diagnosis using peripheral blood smear with remote interpretation in adults living with HIV with moderate to severe anaemia: A prospective study nested within the Kilombero and Ulanga antiretroviral cohort.

Journal: PloS one

Published: February 20, 2023

Antibody Response After Third Vaccination With mRNA-1273 or BNT162b2: Extension of a Randomized Controlled SARS-CoV-2 Noninferiority Vaccine Trial in Patients With Different Levels of Immunosuppression (COVERALL-2).

Antibody Response After Third Vaccination With mRNA-1273 or BNT162b2: Extension of a Randomized Controlled SARS-CoV-2 Noninferiority Vaccine Trial in Patients With Different Levels of Immunosuppression (COVERALL-2).

Journal: Open forum infectious diseases

Published: November 14, 2022

Showing 1-12 of 19

Last Updated: 09/26/2026